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NHPAn important focus in vaccine research is the design of vaccine vectors with low seroprevalence and high
immunogenicity. Replication-incompetent lymphocytic choriomeningitis virus (rLCMV) vectors do not
elicit vector-neutralizing antibody responses, and homologous prime-boost regimens with rLCMV vec-
tors induce boostable and protective T cell responses to model antigens in mice. However, cellular and
humoral immune responses following homologous rLCMV vaccine regimens have not been rigorously
evaluated in non-human primates (NHPs). To test whether rLCMV vectors constitute an effective vaccine
platform in NHPs, we developed rLCMV vectors expressing SIVmac239 Env and Gag antigens and
assessed their immunogenicity in mice and cynomolgus macaques. Immunization with rLCMV vaccine
vectors expressing SIV Env and Gag was effective at generating SIV-specific T cell and antibody responses
in both mice and NHPs. Epitope mapping using SIV Env in C57BL/6 mice demonstrated that rLCMV vec-
tors induced sustained poly-functional responses to both dominant and subdominant epitopes. Our
results suggest the potential of rLCMV vectors as vaccine candidates. Future SIV challenge experiments
in rhesus macaques will be needed to assess immune protection by these vaccine vectors.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction virus (LCMV), which is a widely characterized murine virus thatThe failure of the adenovirus serotype 5 (Ad5)-based vaccine in
the STEP clinical trial has led to the search for alternative vaccine
vectors with distinct immunological properties. Currently, the can-
didate vaccine portfolio is limited in terms of vector diversity, and
a great focus has been to develop adenovirus-, cytomegalovirus-,
and poxvirus-based vectors [1–5]. The characterization of novel
alternative vaccine platforms may provide additional versatility
for vaccine development, especially for use in populations with
pre-existing immunity to other vaccine vectors [6].
In an attempt to expand the current vaccine portfolio, we have
harnessed the immunogenicity of lymphocytic choriomeningitisexhibits tropism for antigen presenting cells, especially macro-
phages and dendritic cells, and induces potent adaptive immune
responses. The incidence of LCMV infections in human populations
is low and clinical manifestations are rare, and thus, the virus does
not represent a major health concern [7,8]. However, severe LCMV
infections have been reported in immunocompromised patients
who receive solid organ transplants [9], and such infections have
been shown to accelerate transplant rejection [10,11].
We have developed novel replication-defective LCMV vectors
(rLCMV) that are not impeded by pre-existing humoral immunity
following homologous boosting [12]. This is, at least in part, due
to glycosylation of the LCMV surface protein (GP), which impairs
the capacity of GP specific antibodies to neutralize the virus [13].
Moreover, rLCMV vectors do not encode the GP gene, and the vac-
cinee’s immune system is therefore only exposed to the minute
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while de novo synthesis of GP as immunogen in the vaccinee is
excluded. As a result, multiple homologous immunizations with
rLCMV vectors result in undetectable rLCMV neutralization, thus
allowing for robust transgene antigen delivery to boost vaccine-
induced responses [12]. Moreover, we have previously shown sev-
eral benefits of rLCMV vectors, including their potent CD8 T cell
responses [12]. Although we have demonstrated partial immune
protection against SIVsmE660 challenges following mismatch Env
vaccination by Ad5 prime and rLCMV boost in rhesus macaques
[14], the effect of homologous rLCMV boosting on adaptive
immune responses in NHP models has not previously been
evaluated.
In this study, we designed novel rLCMV vectors expressing SIV-
mac239 Env and Gag antigens, and we demonstrate their immuno-
genicity in mice and cynomolgus macaques. We also show that
non-replicating rLCMV vectors can provide substantial immune
protection against chronic LCMV challenges in mice. These results
suggest that rLCMV vectors may be exploited for the development
of prophylactic vaccines against infectious diseases or for
immunotherapy of cancer, thus expanding the current vaccine
portfolio.2. Materials and methods
2.1. Animals and immunizations
Six to eight week old C57BL/6 mice were purchased from Jack-
son Laboratories (Bar Harbor, ME), and were immunized intramus-
cularly (i.m) with 105 FFU of replication incompetent LCMV vectors
(rLCMV) expressing SIVmac239 Env and Gag. For viral challenges,
chronic LCMV Cl-13 was injected intravenously (i.v.) via the lateral
tail vein at 2  106 PFU per mouse. The mouse experiments in
Figs. 2–4 included a total of 7 rLCMV-Env vaccinated mice, 7
rLCMV-13-Gag vaccinated mice, and 7 unvaccinated mice (one
experiment with n = 3 mice/per group and another experiment
with n = 4 mice/per group). Cynomolgus macaques were used for
testing the immunogenicity of rLCMV at different doses (Group I
received 2  107 FFU, Group II received 2  106 FFU, and Group III
received 2  105 FFU of rLCMV), each group consisting of 4 maca-
ques. Cynomolgus macaques were housed at Bioqual (Rockville,
MD). Immune responses were assessed at various time points
using Env-specific ELISA, luciferase-based TZM-bl neutralization
assays, microneutralization assay, ELISPOTs, and multiparameter
intracellular cytokine (ICS) assays. Sera or peripheral blood
mononuclear cells (PBMCs) were harvested and used for all
immunological assays. All experiments were performed with
approval of the appropriate Institutional Animal Care and Use
Committees (IACUC).2.2. Viral vector purification
The rLCMV vectors were generated and titrated as described
previously [23,24]. Briefly, the coding sequence (cDNA) of individ-
ual vaccine antigens was generated by chemical synthesis by Gen-
script (USA) and inserted into a plasmid encoding a GP-deleted S
segment of LCMV clone 13 under the control of a murine pol I pro-
moter. SIV gag and gp140 antigen sequences used were derived
from SIV mac 239 (Genbank accession number M33262). BHK-21
cells genetically engineered to express the LCMV GP protein were
transfected with plasmids of the vector rescue system and vectors
were harvested from supernatant of transfected cell after a blind
passage of cells and supernatant.
rLCMV-gag and rLCMV-env vector stocks were generated in
30 ml cultures of serum-free suspension HEK293 production celllines (293-GP) genetically engineered to express the LCMV GP pro-
tein. Cells were seeded in shake flasks at densities of 3  105 cells/
ml in 30 ml CDM4HEK293 medium (GE Healthcare) supplemented
with 4 mM stable Glutamine and 100 lg/ml Geneticin, and
infected with rescued vector material at an MOI of 0.001. At day
3 post infection, supernatants from shake flasks were cleared from
cells and debris by low speed centrifugation (500g, 5 min at
2–8 C), aliquoted and frozen at <60 C. To assess vector growth
kinetics, 293-GP cells were seeded and infected as above. Aliquots
from the individual cultures were drawn at 2, 24, 48, 72 and 96 h
post-infection, cleared as above, and frozen at <60 C.
For nonhuman primate studies, viral vectors encoding the gag
and env gp140 transgenes from SIV mac239 were each produced
in 10 L disposable bioreactors (Eppendorf, Germany) using vector
stocks as seed material. The cell substrate for production was a
complementing HEK293 cell line expressing LCMV GP. The produc-
tion cells were seeded in CDM4HEK293 medium, cultivated and
infected using the aforementioned viruses. During the whole culti-
vation the parameters like pH, DOT, T and PIV were controlled.
When the vector propagation peaked, the cell suspension was har-
vested using serial Sartobind PP3 depth filtration units. Following
DNA degradation using Benzonase (EMPROVE, Merck Millipore),
vector concentration and purification was performed by bind-
elute mode chromatography using a cation exchange column. Post
chromatography buffer exchange into a physiological buffer was
performed by 300 K Hollowfiber tangential flow filtration (GE
Healthcare). The vector product was sterilized with a Millipak filter
unit (Merck Millipore).
The gag and env sequences encoded by rLCMV vectors were
analyzed by consensus sequencing and expression of the proteins
was verified by Western blotting of vector infected cells using
SIV mac239 gag- or env-specific antibodies.2.3. Viral titration
Infectious vector titers were determined by a focus formation
assay using an anti-LCMV NP antibody (VL-4; Bio X Cell, Lebanon,
NH). Briefly, monolayers of adherent LCMV GP-expressing HEK293
cells in 24-well plates were infected with serial dilutions of virus
stock, incubated for 48 h, then fixed and stained with the anti-NP
antibody. The number of foci was determined, and the virus titer
was calculated. Titration of LCMV in mouse challenge studies
was performed on VERO E6 cell (ATCC) monolayers by standard
plaque assay as previously shown [15]. In brief, three ten-fold
serial dilutions from serum samples were distributed on top of
the VERO E6 cell monolayers in six well plates (>80% confluent).
Plates were incubated for a total of 60 min manually rocking every
10 min. After this, a 1:1 solution of 1% agarose in 2  199 media
(Gibco, Life Technologies) was carefully overlaid on top of the
monolayers, and four days after, a 1:1 solution of 1% agarose in
2  199 media with 1:50 neutral red was pipetted on top of each
well. Plaques were counted at day 5 based on neutral red exclusion
using a transluminator.2.4. Flow cytometry
Mouse PBMCs were stained with anti-CD8a (53–6.7), -CD4
(RM4-5), -CD44 (IM7). All surface anti-mouse antibodies were
purchased from BD Pharmingen, except for CD44 (Biolegend).
Biotinylated MHC I monomers (to detect LCMV NP396- or SIV
AL11-specific CD8 T cell responses) were obtained from the NIH
Tetramer Facility. PBMCs from cynomolgus macaques were stained
with anti-CD3 (SP34-2), -CD4 (L200), -CD8 (RPA-T8), -CD69 (FN50).
Intracellular cytokine staining for IFN-c, TNFa, and IL-2 was per-
formed with the Cytofix/Cytoperm kit (BD Biosciences). Samples
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analyzed using FlowJo (Treestar).
2.5. Elispots assays
IFNc-ELISPOT assays were performed using PBMCs from
cynomolgus macaques stimulated with SIVmac239 Gag, Env1,
Env2 peptide pools. We mapped SIVmac239 Env CD8 T cell epi-
topes in C57BL/6 mice using overlapping peptide pools (JPT, Berlin,
Germany). Peptide pools consisted of 15-mer peptides overlapping
by 11, which spanned the entire SIVmac239 Env protein. Peptides
were purified to >80% for routine usage, or >95% for ‘‘high purity”
as specifically indicated in Fig. 3.
2.6. Luciferase-based TZM-bl neutralization assays
These assays were performed using pseudotyped SIV, and CCR5
and CD4 expressing Hela cells as previously shown [16].
2.7. LCMV microneutralization assay
ARPE-19 cells (ATCC CRL-2302) were seeded in DMEM:F12 with
10% heat-inactivated FBS in half-area flat-bottom 96-well tissue
culture plates three days prior to infection. Serial 2-fold dilutions
of test sera, pre-incubated at 56 C for 30 min to inactivate comple-
ment, were prepared in DMEM:F12 containing 25% heat-
inactivated FBS in order to maintain a constant concentration of
serum. GFP-expressing rLCMV was diluted in serum-free DMEM:
F12 medium to obtain a suspension that generates 80–150 NP-
positive cells per well and incubated with the serum dilutions at
37 C for 1 h. The culture medium was removed and replaced with
50 ll of virus/serum mixture. 50 ll of DMEM:F12 medium con-
taining 10% heat-inactivated FBS was added to each well and the
plates were incubated overnight at 37 C. The medium was
removed, the cells were washed with PBS and fixed with cold
80% acetone for 25–30 min at 4 C. Fifty ll of anti-NP monoclonal
antibody (VL-4; Bio X cell, West Lebanon, NH) diluted to 1 lg/mlFig. 1. Generation of rLCMV vectors expressing SIV antigens. (A) Diagram adapted from
(B) Replication kinetics of the vectors in 293-GP cells. Cells were infected with vectors
for titration. A rLCMV vector expressing green fluorescent protein (rLCMV-GFP) w
propagation.in PBS with 2% dry milk was added for 1 h at 37 C before washing
three times in PBS. Fifty ll of biotin-labeled goat anti-rat IgG
(Sigma) diluted 1:1000 in PBS with 2% dry milk was added for
1 h at 37 C. Following washing three times in PBS, 50 ll of HRP-
streptavidin (Dako, Glostrup, Denmark) diluted 1:1000 in PBS with
2% dry milk was added for 30 min at 37 C. Following washing four
times in PBS, TrueBlue (KPL, Gaithersburg, MD) was added for
15 min at room temperature in the dark. Stained plates were rinsed
with distilled water, air dried, and stored in the dark until manual
reading under a microscope.
2.8. Statistical analysis
Statistical analyses were performed using two-tailed paramet-
ric Mann-Whitney tests in GraphPad Prism software.
3. Results
3.1. Construction of rLCMV vectors
Replication incompetent rLCMV Cl-13 vectors were designed as
previously shown [12]. The LCMV GP gene was exchanged with the
SIV mac239 Env and Gag transgenes, respectively, producing two
individual vectors (Fig. 1A). Correctness of the gag and env
sequences encoded by LCMV vectors was confirmed by consensus
sequencing and expression of the proteins was verified by Western
blotting of vector infected cells using SIV mac239 gag- or env-
specific antibodies (data not shown). The two vectors replicated
robustly in cultured trans-complementing LCMV GP-expressing
HEK293 cells (Fig. 1B).
3.2. rLCMV vectors are immunogenic in mice
We immunized C57BL/6 mice i.m. with 105 FFU of rLCMV vec-
tors expressing SIVmac239 Gag or Env, followed by homologous
boosting after more than 100 days (Fig. 2A). This resulted in robust
induction of SIV-specific antibody responses (Fig. 2B), and CD8 TFlatz and Pinschewer (Nature Medicine 2010) depicting how vectors were made.
at MOI of 0.001 and aliquots were drawn at 2, 24, 48, 72 and 96 h post-infection
as used as a control to show that the SIV transgenes did not affect vector
Fig. 2. rLCMV vectors expressing SIVmac239 Gag and Env are immunogenic in
mice. (A) Experimental layout. (B) Summary of SIV Env-specific antibody responses
by ELISA. (C) Summary of Gag- and Env-specific CD8 T cell responses by ICS. Mice
were first primed at day 0 and boosted homologously after day 100 to assess
cellular immune responses in PBMC (ICS) and sera (ELISA). Error bars indicate SEM.
Data are from 2 experiments, n = 3–4 per group/experiment.
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day 9 after rLCMV prime, contracted by day 100, but were potently
recalled following boost immunization. rLCMV-env vectors
induced higher levels of IFNc expressing CD8 T cells than rLCMV-
gag vectors (Fig. 2C). Hence, we sought to determine if this
reflected a potent response against a single epitope, or responses
against multiple epitopes. We identified a dominant and subdom-
inant CD8 T cell epitope within the SIVmac239 Env response
(Fig. 3A). Subsequent mapping identified the minimal dominant
epitope as Env233-241 (CAPPGYALL) (Fig. 3B–D) and the minimal
subdominant epitope as Env465-473 (SLIANIDWI) (Fig. 3E–G).
With these novel epitopes mapped, PBMCs were collected from
rLCMV-env homologous prime-boosted mice on day 400 post-
immunization and restimulated individually with the dominant
Env233-241 and subdominant Env465-473 peptides. Robust IFN-
c production by vaccine-elicited CD8 T cells was detected in
response to both epitopes (Fig. 3H). Additionally, a majority of
CD8 T cells specific for Env233-241 and Env465-473 produced
TNF-a and/or IL-2 in addition to IFN-c (Fig. 3I). Thus, rLCMV vector
vaccination can induce poly-functional memory CD8 T cellresponses against dominant and subdominant epitopes, which
can be efficiently boosted upon re-administration of the vector.
3.3. rLCMV vectors protect against chronic LCMV challenge in mice
In the experiments above, we confirmed that non-replicating
rLCMV vectors induce cellular and humoral responses to heterolo-
gous vaccine antigens in mice. To assess protection by vaccine-
induced immune responses to the vector, we performed LCMV
challenges in rLCMV-vaccinated mice (Fig. 4A). We first vaccinated
mice with non-replicating rLCMV expressing SIVmac239 Gag and
Env (105 FFU), and after 200 days, we challenged them
intravenously with the persistence-prone LCMV strain Clone 13
(Cl-13), which normally induces a chronic infection in mice
[17,18]. rLCMV vaccinated mice exhibited 27.8-fold greater num-
bers of LCMV-specific CD8 T cells (H-2Db-NP396) in blood at day
5 following chronic LCMV Cl-13 challenge relative to unvaccinated
mice (Fig. 4B and C). Although LCMV titers were not statistically
different at day 5 post-challenge (p = 0.07), mice that had received
the non-replicating rLCMV vaccine exhibited significant viral con-
trol by day 15 post-challenge (1763-fold lower viral loads, p = 0.03)
relative to unvaccinated mice (Fig. 4D). Of note, rLCMV vectors
(which are based on the chronic LCMV Cl-13 backbone) did not
increase T regulatory cells, which normally occurs after infection
with replicating Cl-13 [19], suggesting that rLCMV vectors are safe
and do not induce an immunosuppressive environment (Fig. 4E).
These results demonstrate that non-replicating rLCMV vaccines
based on the Cl-13 backbone can protect against a persistent viral
challenge and do not induce increased Treg levels.
3.4. rLCMV vectors are immunogenic in cynomolgous macaques
LCMV is a prototypic arenavirus that is highly immunogenic in
mice and also replicates efficiently in non-human primates [20]. To
validate the immunogenicity of our rLCMV vectors in NHPs, we
vaccinated cynomolgus macaques (Macaca fascicularis) with non-
replicating rLCMV vectors expressing SIVmac239 Gag and Env.
We primed three groups of 4 macaques each with high (group I),
mid (group II), or low (group III) doses (2  107, 2  106, and
2  105 FFU, respectively) of rLCMV-gag/env vectors, followed by
repeated homologous boosting, as indicated in Fig. 5A. As expected,
repetitive homologous boosting with rLCMV-gag and rLCMV-env
vectors resulted in increased T cell responses detected by intracel-
lular cytokine staining (Fig. 5B) and IFN-c ELISPOT assays (Fig. 5C).
There was a pattern of increased responses in the high dose group
(Group I), but the difference was not statistically significant when
compared to the other 2 groups. Importantly, high doses of rLCMV
vaccines induced enhanced effector memory differentiation
(CD28-CD95+) on total, as well as SIV-specific CD8 T cells
(Fig. 6A and B).
In addition, we evaluated humoral responses following immu-
nization with non-replicating rLCMV vectors. The 2  107 FFU dose
(group I) resulted in high Env-specific IgG antibody responses by
ELISA (Fig. 7A). Moreover, this high dose (2  107 FFU) induced
substantial Tier 1A (SIVmac251.TCLA.15) neutralization in stan-
dard luciferase-based TZM-bl assays (Fig. 7B). Tier 1A-
neutralizing responses were also consistently mounted upon
administration of rLCMV vectors at low or medium dose (Group
II, III), respectively, although at somewhat lower titers than in
the high-dose group (Group I). No neutralizing antibody responses
were detected against Tier 2 pseudoviruses using luciferase-based
TZM-bl assays (SIVmac251.30 ID50 titer <1:20; data not shown).
We also assessed the ability of sera from animals immunized with
one or two doses of the vaccines to neutralize LCMV infection of
human epithelial cells in vitro. Sera from week 0 (baseline), week
8 (following one dose), and week 12 (following two doses) showed
Fig. 3. Mapping of SIVmac239 Env CD8 T cell epitopes in C57BL/6 mice. In panels A-G, C57BL/6 mice were immunized intramuscularly with Ad26-SIVmac239 Env. Purified
splenocytes were re-stimulated with the indicated SIVenv239 peptide or peptide pool. (A) IFNc expression by CD8 T cells in response to stimulation with the indicated
SIVmac239 peptide pool or the constituent subpools of the indicated pool. (B) Mapping of the dominant peptide epitope within subpool 6. (C) Identification of the minimal
CD8 T cell epitope within the peptide identified in subpool 6, as measured by IFNc expression in response to log-fold dilution of peptide. (D) Response kinetics for subpool 6
mapping using high purity peptides against the two strongest responding peptides identified in panel C. This was performed to confirm that the stronger responses in the
‘‘CAPPGYALL” epitope did not reflect degradation impurities. (E) Mapping of the subdominant peptide epitope within subpool 12. (F) Identification of the minimal CD8 T cell
epitope within the peptide identified in subpool 12, as measured by IFNc expression in response to log-fold dilution of peptide. Mapping was performed down to the 9-mer
level. (G) Identification of the minimal CD8 T cell epitope within the 9-mer peptide identified in subpool 12 (‘‘SLIANIDWI”), as measured by IFNc expression in response to
log-fold dilution of peptide. (H, I) C57BL/6 mice were immunized intramuscularly with rLCMV-SIVmac239 Env and >1 year post-immunization Env-specific CD8 T cell
responses were assessed against the dominant (Env233-241; CAPPGYALL) or subdominant (Env465-473; SLIANIDWI) epitopes. (H) Representative staining and group
summaries for IFNc expression by CD8 T cells in response to ex vivo stimulation with the dominant and subdominant epitope peptides. (I) Polyfunctionality of CD8 T cells
from rLCMV-SIVmac239 Env immunized animals specific for the dominant and subdominant epitopes. Data are from two experiments, n = 3–4 per group/experiment.
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Fig. 4. rLCMV vectors protect against a chronic LCMV Cl-13 challenge. (A) Experimental layout. (B) Representative FACS plots showing NP-specific CD8 and CD4 T cell
responses before and after challenge by ICS. (C) Summary of NP-specific CD8 and CD4 T cell responses before and after challenge by ICS. (D) Viral control in sera. (E) Treg levels
in PBMCs. Mice were challenged i.v. with 2  106 PFU LCMV Cl-13, and bled at day 5 to assess LCMV NP-specific CD8 T cell responses by ICS or viral loads by plaque assays.
Error bars indicate SEM. Data are from 2 experiments, n = 3–4 per group/experiment.
Fig. 5. rLCMV vectors induce SIV-specific T cell responses in cynomolgus macaques. (A) Experiment outline. (B) Longitudinal analyses of Gag and Env-specific CD8 and CD4 T
cell responses by ICS at week 49. (C) Representative FACS plots of CD8 and CD4 T cell responses by ICS. (D) Longitudinal analyses of Gag and Env-specific T cell responses by
ELISPOTs. Error bars indicate SEM.
6 P. Penaloza MacMaster et al. / Vaccine 35 (2017) 1–9
Fig. 6. Effect of rLCMV vaccine dose on T cell subset differentiation. (A) Representative FACS plots showing effector memory and central memory subsets on total CD8 T cells
and SIV Env-specific CD8 T cells. (B) Summary of effector memory and central memory subsets on total CD8 T cells and SIV Env-specific CD8 T cells. Data are from week 48
from the same macaque study as in Fig. 4, which included 4 macaques per group. Error bars indicate SEM.
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tested (data not shown).4. Discussion
We have evaluated the immunogenicity and boosting capacity of
replication-incompetent rLCMV vectors inmice andNHPs. Immuniza-
tion of mice with rLCMV vectors expressing SIVmac239 Env and Gag
immunogens resulted in persistent CD8+ T cell responses (Figs. 2–4).We were also able to map the H-2b-restricted immunodominant and
subdominant CD8 T cell epitopes in SIVmac239 Env (Env233-241
and Env465-473, respectively). Following challenge with LCMV Cl-
13, virus-specific CD8 T cell responses elicited by replication-
incompetent rLCMV vectors expanded robustly (27.8-fold greater
expansion relative to unvaccinated at day 5, p = 0.04), and resulted in
viral control by day 15 post-challenge. Massive CD8 T cell recall was
a feature of boosting with replicating LCMV Cl-13, consistent with
some of our prior data showing that the replicative capacity of the
boosting antigen can influence the recall potential of primed immune
Fig. 7. rLCMV vectors induce SIV-specific antibody responses in cynomolgus macaques. (A) Longitudinal analyses of Env-specific antibody responses by ELISA. SIVmac239
Env protein was used as coating antigen and secondary antibody was conjugated to HRP. (B) Longitudinal analyses of SIV neutralizing antibody responses by TZM-bl assays. P-
values at week 10 post-immunization are indicated relative to Group I. Error bars indicate SEM.
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mice normally results in chronic infection and exhaustion of primary
immune responses [17,18,22–29], but our data show thatwhen LCMV
Cl-13 isadministeredasaboost, it results inan impressiveexpansionof
anamnestic T cell responses. Therefore, the order of prime-boost
immunizations is critical for rational vaccine design, and our results
suggest the potential of live replicating agents as boosts. However,
future studies should rigorously assess the safety of replicating vectors
as boosting antigens.
Moreover, we tested the immunogenicity of rLCMV vectors in
cynomolgus macaques in dose-escalating studies, and we observed
that a 2  107 FFU dose resulted in higher SIV-specific T cell
responses relative to lower doses. Importantly, for all dosage
groups, the frequencies of antigen specific T-cell responses could
be augmented after each homologous booster vaccination. It was
interesting that higher doses of rLCMV vaccines induced biased
effector memory CD8 T cell differentiation. Effector memory CD8
T cells are known to mediate rapid cytotoxic killing following anti-
gen challenge [30–32], thus representing a potential advantage of
increasing vaccine dose, especially in the context of SIV challenge,
where immediate cytotoxic function may be critical even hours
after initial mucosal exposure [33].
Although the level of virus neutralization by humoral responses
is known to increase with time following SIV/HIV [34–41], and
chronic LCMV infections [13], likely as a result of continuous
antigen-driven germinal center reactions with concomitant affinity
maturation, it is currently unclear whether multiple homologous
boosting during vaccination could lead to the same result. Impor-
tantly, our studies suggest that, different from chronic replicating
infection with wild type LCMV, repetitive homologous vaccination
with rLCMV vectors does not lead to LCMV-neutralizing antibody
titers, which would prevent vector re-administration. With respect
to rLCMV-induced SIV-specific antibodies, it remains unclear why
SIV-neutralizing antibodies peaked after the first rLCMV vaccina-
tion, but did not measurably increase after multiple rLCMV boosts,
whereas binding antibodies (measured by ELISA) did. Whether the
same may apply to heterologous prime-boost regimens, such as
those involving poxvirus- or adenovirus-based vectors, remains
to be determined. Our results demonstrate, however, that higher
doses of rLCMV vaccine result in higher virus neutralizationrelative to lower doses. These findings are, therefore, novel and
important for rational vaccine design.
The rLCMV vaccine platform offers various attractive features
such as its robust induction of dendritic cell activation, and the fact
that these vectors bypass LCMV (vector-specific, but not
transgene-specific) neutralizing antibody responses [12]. More-
over, a prior study showed the high boosting potential of a mis-
matched Ad5 prime, rLCMV boost vaccine regimen in a model of
SIVsmE660 challenge in rhesus macaques [14]. Our data extend
these prior results by assessing the effect of a homologous, dose-
escalating rLCMV prime-boost regimens in NHPs, focusing longitu-
dinally on both the humoral and cellular immune responses.
Importantly, we evaluate the effects of homologous vaccine dosing
in determining the levels of neutralizing antibodies. Future studies
should assess whether rLCMV vectors expressing SIV envelopes
can induce additional neutralization capacity and provide immune
protection against heterologous SIV challenges in rhesus maca-
ques, as well as other viral and bacterial diseases.Acknowledgments
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